A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop bispecific antibody-based T-cell engager (TCE) therapies for autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results